Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 7/20 | 0.61 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7964192 | 0.90 | PLA2G2A (0.76) | PLA2G2AADORA1L3MBTL1CHRM1 | |
| SCHEMBL6775064 | 0.80 | PLA2G2A (0.65) | PLA2G2ATP53MAPTLMNAMTNR1A | |
| SCHEMBL6775272 | 0.78 | PLA2G2A (0.51) | PLA2G2AL3MBTL1CHRM1MTNR1AMTNR1B | |
| SCHEMBL7961599 | 0.78 | PLA2G2A (0.76) | PLA2G2A | |
| SCHEMBL6775267 | 0.78 | PLA2G2A (0.51) | PLA2G2AL3MBTL1CHRM1MTNR1AMTNR1B | |
| SCHEMBL7965269 | 0.76 | PLA2G2A (0.60) | PLA2G2ALMNAMTNR1AMTNR1B | |
| SCHEMBL1607281 | 0.76 | MAPT (0.53) | PLA2G2AMAPK1MAPTLMNA | |
| SCHEMBL5625905 | 0.76 | ADORA1 (0.78) | SERPINE1ADORA1L3MBTL1MAPK1MAPT | |
| SCHEMBL30914311 | 0.75 | MAPT (0.55) | ADORA1TP53MAPTLMNA | |
| SCHEMBL12484505 | 0.75 | LTB4R (0.49) | PLA2G2ATP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6713645-B1 | INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK | ELI LILLY AND COMPANY | 2004-03-30 | — | — | US | disclosed |
| EP-0950661-B1 | Substituted tricyclics useful in sPLA2 induced diseases | LILLY CO ELI (US) | 2003-11-12 | — | — | EP | disclosed |
| EP-1156050-A2 | Substituted tricyclics useful in sPLA2 induced diseases | ELI LILLY AND COMPANY (US) | 2001-11-21 | — | — | EP | disclosed |
| US-6177440-B1 | THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR | ELI LILLY AND COMPANY | 2001-01-23 | — | — | US | disclosed |
| EP-0950661-A1 | Substituted tricyclics useful in sPLA2 induced diseases | ELI LILLY AND COMPANY (US) | 1999-10-20 | — | — | EP | disclosed |